Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
about
Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database.Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience.Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study.Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.Effect of dimethyl fumarate on renal disease progression in a genetic ortholog of nephronophthisis.Persistence to oral disease-modifying therapies in multiple sclerosis patients.Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
P2860
Q33736215-DA5C3363-6058-4347-BCCB-82407DDCDF22Q38608929-E656ABB1-FD04-468E-9E0F-1B754B557582Q40048497-A884AEF2-F3FB-4575-A74E-0D0A05B94449Q47198260-8894FF36-5B76-4E3E-A3F0-B74D2E3B5562Q47612186-504ADBE7-C516-4901-B599-805148BE2F33Q47986992-C344F34C-475B-47AC-BA42-0D499BD773BDQ48664001-15E39B19-390D-4657-9301-7D1E9096A25CQ49720568-1E7B2FE6-8FA6-4EA7-94C3-0069F98DE443Q50046953-38C81981-FBDC-4F66-80E4-1D8B8101651CQ50498068-DB1C49C1-9310-4973-9F02-89693D9CD804Q58805531-0AB7C44D-F566-48AD-B24D-08EAE3E09353
P2860
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Comparative efficacy and disco ...... ractice at 12-month follow-up.
@en
type
label
Comparative efficacy and disco ...... ractice at 12-month follow-up.
@en
prefLabel
Comparative efficacy and disco ...... ractice at 12-month follow-up.
@en
P2093
P1476
Comparative efficacy and disco ...... practice at 12-month follow-up
@en
P2093
Carrie M Hersh
Claire Hara-Cleaver
Jeffrey A Cohen
Robert A Bermel
Robert J Fox
Samuel Cohn
Thomas E Love
P356
10.1016/J.MSARD.2016.08.002
P577
2016-08-08T00:00:00Z